Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Operating Income (2022 - 2025)

Entrada Therapeutics has reported Operating Income over the past 4 years, most recently at -$42.2 million for Q4 2025.

  • Quarterly results put Operating Income at -$42.2 million for Q4 2025, down 619.41% from a year ago — trailing twelve months through Dec 2025 was -$157.9 million (down 435.87% YoY), and the annual figure for FY2025 was -$157.9 million, down 435.87%.
  • Operating Income for Q4 2025 was -$42.2 million at Entrada Therapeutics, up from -$47.1 million in the prior quarter.
  • Over the last five years, Operating Income for TRDA hit a ceiling of $53.4 million in Q2 2024 and a floor of -$47.1 million in Q3 2025.
  • Median Operating Income over the past 4 years was -$21.7 million (2024), compared with a mean of -$13.2 million.
  • Biggest five-year swings in Operating Income: skyrocketed 465.28% in 2024 and later tumbled 619.41% in 2025.
  • Entrada Therapeutics' Operating Income stood at -$25.6 million in 2022, then soared by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then tumbled by 619.41% to -$42.2 million in 2025.
  • The last three reported values for Operating Income were -$42.2 million (Q4 2025), -$47.1 million (Q3 2025), and -$46.8 million (Q2 2025) per Business Quant data.